Summary
45.27 -1.83(-3.89%)09/06/2024
Vericel Corp (VCEL)
Vericel Corp (VCEL)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -3.74 | -12.45 | -3.37 | -1.24 | 0.24 | 35.01 | 180.48 | -95.96 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 45.27 | |
| Open | 47.08 | |
| High | 47.40 | |
| Low | 44.95 | |
| Volume | 134,318 | |
| Change | -1.76 | |
| Change % | -3.74 | |
| Avg Volume (20 Days) | 195,158 | |
| Volume/Avg Volume (20 Days) Ratio | 0.69 | |
| 52 Week Range | 30.18 - 54.09 | |
| Price vs 52 Week High | -16.31% | |
| Price vs 52 Week Low | 50.00% | |
| Range | -3.84 | |
| Gap Up/Down | -0.80 | |
Fundamentals | ||
| Market Capitalization (Mln) | 2,217 | |
| EBIDTA | -1,832,000 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 52.07 | |
| Book Value | 4.7240 | |
| Earnings Per Share | -0.0700 | |
| EPS Estimate Current Quarter | 0.1700 | |
| EPS Estimate Next Quarter | -0.0900 | |
| EPS Estimate Current Year | 0.0800 | |
| EPS Estimate Next Year | 0.4900 | |
| Diluted EPS (TTM) | -0.0700 | |
| Revenues | ||
| Profit Marging | -0.0161 | |
| Operating Marging (TTM) | 0.1959 | |
| Return on asset (TTM) | -0.0129 | |
| Return on equity (TTM) | -0.0152 | |
| Revenue TTM | 197,516,000 | |
| Revenue per share TTM | 4.1500 | |
| Quarterly Revenue Growth (YOY) | 0.2330 | |
| Quarterly Earnings Growth (YOY) | 1.0450 | |
| Gross Profit (TTM) | 109,788,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 303.0303 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 9.7776 | |
| Revenue Enterprise Value | 11.0764 | |
| EBITDA Enterprise Value | 763.8830 | |
| Shares | ||
| Shares Outstanding | 48,290,200 | |
| Shares Float | 44,662,607 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 0.79 | |
| Institutions (%) | 110.92 | |
08/29 09:17 EST - globenewswire.com
Vericel to Present at the Morgan Stanley Global Healthcare Conference on Friday, September 6, 2024
CAMBRIDGE, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, and Joe Mara, CFO, will participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference at 1:05 p.m. ET on Friday, September 6, 2024.
Vericel to Present at the Morgan Stanley Global Healthcare Conference on Friday, September 6, 2024
CAMBRIDGE, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, and Joe Mara, CFO, will participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference at 1:05 p.m. ET on Friday, September 6, 2024.
08/26 07:45 EST - globenewswire.com
Vericel Announces FDA Approval and Commercial Availability of MACI Arthro
First Restorative Biologic Cartilage Repair Product Approved for Arthroscopic Administration Targets the Largest Segment of MACI's $3 Billion Addressable Market CAMBRIDGE, Mass., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) expanding the MACI® (autologous cultured chondrocytes on porcine collagen membrane) label to include arthroscopic delivery of MACI to repair symptomatic single or multiple full-thickness cartilage defects of the knee up to 4 cm2 in size.
Vericel Announces FDA Approval and Commercial Availability of MACI Arthro
First Restorative Biologic Cartilage Repair Product Approved for Arthroscopic Administration Targets the Largest Segment of MACI's $3 Billion Addressable Market CAMBRIDGE, Mass., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) expanding the MACI® (autologous cultured chondrocytes on porcine collagen membrane) label to include arthroscopic delivery of MACI to repair symptomatic single or multiple full-thickness cartilage defects of the knee up to 4 cm2 in size.
08/15 16:05 EST - globenewswire.com
Vericel Announces FDA Approval of NexoBrid for the Treatment of Pediatric Patients with Severe Thermal Burns
Approval Expands NexoBrid Target Customer Base to Include Approximately 20 Pediatric Burn Centers CAMBRIDGE, Mass., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the U.S. Food and Drug Administration (FDA) has approved a pediatric indication for NexoBrid® (anacaulase-bcdb) for eschar removal in pediatric patients with deep partial-thickness and/or full-thickness thermal burns.
Vericel Announces FDA Approval of NexoBrid for the Treatment of Pediatric Patients with Severe Thermal Burns
Approval Expands NexoBrid Target Customer Base to Include Approximately 20 Pediatric Burn Centers CAMBRIDGE, Mass., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the U.S. Food and Drug Administration (FDA) has approved a pediatric indication for NexoBrid® (anacaulase-bcdb) for eschar removal in pediatric patients with deep partial-thickness and/or full-thickness thermal burns.
08/07 08:30 EST - globenewswire.com
Vericel to Present at the Canaccord Genuity Growth Conference on Wednesday, August 14, 2024
CAMBRIDGE, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, will present at the Canaccord Genuity Growth Conference at 3:00 p.m. ET on Wednesday, August 14, 2024.
Vericel to Present at the Canaccord Genuity Growth Conference on Wednesday, August 14, 2024
CAMBRIDGE, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, will present at the Canaccord Genuity Growth Conference at 3:00 p.m. ET on Wednesday, August 14, 2024.
08/05 13:01 EST - zacks.com
What Makes Vericel (VCEL) a New Strong Buy Stock
Vericel (VCEL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
What Makes Vericel (VCEL) a New Strong Buy Stock
Vericel (VCEL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
08/01 15:58 EST - seekingalpha.com
Vericel Corporation (VCEL) Q2 2024 Earnings Call Transcript
Vericel Corporation (NASDAQ:VCEL ) Q2 2024 Results Conference Call August 1, 2024 8:30 AM ET Company Participants Eric Burns - Vice President of Finance & Investor Relations Nick Colangelo - Chief Executive Officer Joe Mara - Chief Financial Officer Conference Call Participants Ryan Zimmerman - BTIG Mike Kratky - Leerink Partners Josh Jennings - TD Cowen Jeff Cohen - Ladenburg Thalmann & Company Swayampakula Ramakanth - HCW Operator Ladies and gentlemen, thank you for standing by. Welcome to Vericel's Second Quarter 2024 Conference Call.
Vericel Corporation (VCEL) Q2 2024 Earnings Call Transcript
Vericel Corporation (NASDAQ:VCEL ) Q2 2024 Results Conference Call August 1, 2024 8:30 AM ET Company Participants Eric Burns - Vice President of Finance & Investor Relations Nick Colangelo - Chief Executive Officer Joe Mara - Chief Financial Officer Conference Call Participants Ryan Zimmerman - BTIG Mike Kratky - Leerink Partners Josh Jennings - TD Cowen Jeff Cohen - Ladenburg Thalmann & Company Swayampakula Ramakanth - HCW Operator Ladies and gentlemen, thank you for standing by. Welcome to Vericel's Second Quarter 2024 Conference Call.
08/01 10:06 EST - zacks.com
Vericel Corporation (VCEL) Reports Q2 Loss, Lags Revenue Estimates
Vericel Corporation (VCEL) came out with a quarterly loss of $0.10 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.11 per share a year ago.
Vericel Corporation (VCEL) Reports Q2 Loss, Lags Revenue Estimates
Vericel Corporation (VCEL) came out with a quarterly loss of $0.10 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.11 per share a year ago.
08/01 07:55 EST - globenewswire.com
Vericel Reports Second Quarter 2024 Financial Results
Total Revenue of $52.7 Million, with MACI Revenue Growth of 21% to $44.1 Million NexoBrid Revenue Growth of 76% Over Prior Quarter Gross Margin of 70% and Adjusted EBITDA Growth of 42% Full-Year Profitability Guidance Raised to 71% Gross Margin and 21% Adjusted EBITDA Margin Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the second quarter ended June 30, 2024.
Vericel Reports Second Quarter 2024 Financial Results
Total Revenue of $52.7 Million, with MACI Revenue Growth of 21% to $44.1 Million NexoBrid Revenue Growth of 76% Over Prior Quarter Gross Margin of 70% and Adjusted EBITDA Growth of 42% Full-Year Profitability Guidance Raised to 71% Gross Margin and 21% Adjusted EBITDA Margin Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the second quarter ended June 30, 2024.
07/22 08:30 EST - globenewswire.com
Vericel Announces Appointment of Karen Mahoney as Chief Human Resources Officer
CAMBRIDGE, Mass., July 22, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the appointment of Karen Mahoney as Chief Human Resources Officer following the retirement of Heidi Hassen, who served as Vericel's Head of Human Resources since September 2010.
Vericel Announces Appointment of Karen Mahoney as Chief Human Resources Officer
CAMBRIDGE, Mass., July 22, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the appointment of Karen Mahoney as Chief Human Resources Officer following the retirement of Heidi Hassen, who served as Vericel's Head of Human Resources since September 2010.
07/18 08:30 EST - globenewswire.com
Vericel to Report Second-Quarter 2024 Financial Results on August 1, 2024
CAMBRIDGE, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its second-quarter 2024 financial results on Thursday, August 1, 2024. Vericel's management will host a conference call and webcast at 8:30 a.m. (ET) to discuss its financial results and business highlights.
Vericel to Report Second-Quarter 2024 Financial Results on August 1, 2024
CAMBRIDGE, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its second-quarter 2024 financial results on Thursday, August 1, 2024. Vericel's management will host a conference call and webcast at 8:30 a.m. (ET) to discuss its financial results and business highlights.
06/27 14:03 EST - investorplace.com
The 3 Highest-Rated Medical Stocks You Can Buy Today
The medical field is a non-negotiable aspect of society. Advanced healthcare is required to combat existing diseases and protect ourselves from new ones.
The 3 Highest-Rated Medical Stocks You Can Buy Today
The medical field is a non-negotiable aspect of society. Advanced healthcare is required to combat existing diseases and protect ourselves from new ones.
06/11 08:30 EST - globenewswire.com
Vericel to Present at the Truist Securities MedTech Conference on Tuesday, June 18, 2024
CAMBRIDGE, Mass., June 11, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, and Joe Mara, CFO, will participate in a fireside chat at the Truist Securities MedTech Conference at 2:30 p.m. ET on Tuesday, June 18, 2024.
Vericel to Present at the Truist Securities MedTech Conference on Tuesday, June 18, 2024
CAMBRIDGE, Mass., June 11, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, and Joe Mara, CFO, will participate in a fireside chat at the Truist Securities MedTech Conference at 2:30 p.m. ET on Tuesday, June 18, 2024.
05/22 08:30 EST - globenewswire.com
Vericel to Present at the Leerink Partners Healthcare Crossroads Conference on Wednesday, May 29, 2024
CAMBRIDGE, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO and Joe Mara, CFO will participate in a fireside chat at the Leerink Partners Healthcare Crossroads Conference at 9:40 a.m. ET on Wednesday, May 29, 2024.
Vericel to Present at the Leerink Partners Healthcare Crossroads Conference on Wednesday, May 29, 2024
CAMBRIDGE, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO and Joe Mara, CFO will participate in a fireside chat at the Leerink Partners Healthcare Crossroads Conference at 9:40 a.m. ET on Wednesday, May 29, 2024.
05/08 14:36 EST - seekingalpha.com
Vericel Corporation (VCEL) Q1 2024 Earnings Call Transcript
Vericel Corporation (NASDAQ:VCEL ) Q1 2024 Earnings Conference Call May 8, 2024 8:30 AM ET Company Participants Eric Burns - Vice President of Finance & Investor Relations Nick Colangelo - Chief Executive Officer Joe Mara - Chief Financial Officer Conference Call Participants Ryan Zimmerman - BTIG Sam Brodovsky - Truist Securities George Sellers - Stephens, Inc. Swayampakula Ramakanth - H.C. Wainwright Operator Ladies and gentlemen, thank you for standing by.
Vericel Corporation (VCEL) Q1 2024 Earnings Call Transcript
Vericel Corporation (NASDAQ:VCEL ) Q1 2024 Earnings Conference Call May 8, 2024 8:30 AM ET Company Participants Eric Burns - Vice President of Finance & Investor Relations Nick Colangelo - Chief Executive Officer Joe Mara - Chief Financial Officer Conference Call Participants Ryan Zimmerman - BTIG Sam Brodovsky - Truist Securities George Sellers - Stephens, Inc. Swayampakula Ramakanth - H.C. Wainwright Operator Ladies and gentlemen, thank you for standing by.
05/08 07:55 EST - globenewswire.com
Vericel Reports First Quarter 2024 Financial Results and Raises Full-Year 2024 Financial Guidance
Total Revenue Increased 25% to $51.3 Million Record First Quarter MACI Revenue of $40.2 Million and Burn Care Revenue Growth of 63% Adjusted EBITDA Growth of 325% Full-Year 2024 Revenue Guidance Raised to $238-$242 Million Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the first quarter ended March 31, 2024.
Vericel Reports First Quarter 2024 Financial Results and Raises Full-Year 2024 Financial Guidance
Total Revenue Increased 25% to $51.3 Million Record First Quarter MACI Revenue of $40.2 Million and Burn Care Revenue Growth of 63% Adjusted EBITDA Growth of 325% Full-Year 2024 Revenue Guidance Raised to $238-$242 Million Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the first quarter ended March 31, 2024.
04/24 08:30 EST - globenewswire.com
Vericel to Report First-Quarter 2024 Financial Results on May 8, 2024
CAMBRIDGE, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its first-quarter 2024 financial results on Wednesday, May 8, 2024. Vericel's management will host a conference call and webcast at 8:30 a.m. (ET) to discuss its financial results and business highlights.
Vericel to Report First-Quarter 2024 Financial Results on May 8, 2024
CAMBRIDGE, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its first-quarter 2024 financial results on Wednesday, May 8, 2024. Vericel's management will host a conference call and webcast at 8:30 a.m. (ET) to discuss its financial results and business highlights.
04/01 08:00 EST - investors.com
The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks
The top five biotech stocks today have several commonalities. Among them are strong ratings.
The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks
The top five biotech stocks today have several commonalities. Among them are strong ratings.
02/29 11:39 EST - seekingalpha.com
Vericel Corporation (VCEL) Q4 2023 Earnings Call Transcript
Vericel Corporation (VCEL) Q4 2023 Earnings Call Transcript
Vericel Corporation (VCEL) Q4 2023 Earnings Call Transcript
Vericel Corporation (VCEL) Q4 2023 Earnings Call Transcript
02/29 10:06 EST - zacks.com
Vericel Corporation (VCEL) Q4 Earnings Beat Estimates
Vericel Corporation (VCEL) came out with quarterly earnings of $0.26 per share, beating the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.12 per share a year ago.
Vericel Corporation (VCEL) Q4 Earnings Beat Estimates
Vericel Corporation (VCEL) came out with quarterly earnings of $0.26 per share, beating the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.12 per share a year ago.
02/29 07:55 EST - globenewswire.com
Vericel Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Full-Year 2024 Financial Guidance
Full-Year 2023 Total Revenue Growth of 20% to $197.5 Million, with Adjusted EBITDA Growth of 40% Fourth Quarter Total Revenue Growth of 23% to $65.0 Million, with Adjusted EBITDA Growth of 50% Fourth Quarter Gross Margin of 75% and Adjusted EBITDA Margin of 34% Full-Year 2024 Total Revenue Guidance of $237 to $241 Million Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the fourth quarter and year ended December 31, 2023, and provided full-year 2024 financial guidance.
Vericel Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Full-Year 2024 Financial Guidance
Full-Year 2023 Total Revenue Growth of 20% to $197.5 Million, with Adjusted EBITDA Growth of 40% Fourth Quarter Total Revenue Growth of 23% to $65.0 Million, with Adjusted EBITDA Growth of 50% Fourth Quarter Gross Margin of 75% and Adjusted EBITDA Margin of 34% Full-Year 2024 Total Revenue Guidance of $237 to $241 Million Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the fourth quarter and year ended December 31, 2023, and provided full-year 2024 financial guidance.